ANTIKOR  

Next-generation Antibody Fragment Drug Conjugates

Sector

Cancer therapeutics

Stage

Pre-clinical

Funding needed

£ 1 000 000

Country

UK

Fragment Drug Conjugates greatly improve delivery of drug payload in malignant cells compared to traditional ADC

FDC need lower doses to act, they are better tolerated and have fewer side effects

ADC market (currently $ 2.0b) expected to more than double by 2020

Strong IP to protect products until 2034

If you want to have more information or you want to review the project, you have to login or register

KEEP REVIEWING

©2023 BioExpert Network

About cookies

This website uses cookies to give you the best user experience. If you continue browsing you are giving your consent for the acceptance of those cookies and the acceptance of our cookies policy.

If you continue to browse and use this website you are agreeing to comply with and be bound by the following Terms of Use

ACEPTAR
Aviso de cookies

Log in with your credentials

or    

Forgot your details?

Create Account

Skip to toolbar